Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543156 | 1.00 | HTR1A (0.59) | HTR1AADRA1DADRA1AADRA1BEGFR | |
| SCHEMBL29855973 | 0.86 | KMT2A (0.54) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL621309 | 0.86 | KMT2A (0.54) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL1337689 | 0.80 | HTR1A (0.61) | HTR1AADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL31337072 | 0.79 | HTR1A (0.59) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL7370612 | 0.79 | HTR1A (0.59) | HTR1AADRA1DADRA1AADRA1BNSD2 | |
| SCHEMBL2178344 | 0.79 | HTR1A (0.59) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL2699726 | 0.79 | HTR1A (0.59) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| Hydrochloric Acid SCHEMBL28298100 | 0.79 | EGFR (0.54) | HTR1AADRA1DADRA1AADRA1BEGFR | |
| SCHEMBL28304013 | 0.79 | SLC40A1 (0.49) | HTR1AADRA1DADRA1AADRA1BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | Jiangsu Yahong Meditech Co. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4623914-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20250289826-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | TSINGHUA UNIVERSITY (CN) | 2025-09-18 | — | — | US | disclosed |
| CN-120035438-A | Use of 8-hydroxyquinoline derivatives | 江苏亚虹医药科技股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12291502-B2 | Topoisomerase II-alpha inhibitors and methods of treating cancer using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-113891879-B | 3, 6-Disubstituted-2-pyridine aldoxime skeleton | 国家科学研究中心 | 2025-03-04 | — | — | CN | disclosed |
| EP-4509494-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | Tsinghua University (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-12209090-B2 | 3,6-disubstituted-2-pyridinaldoxime scaffolds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-01-28 | — | — | US | disclosed |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| US-20170233345-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233345-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| EP-3180006-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017021319-A1 | BROAD SPECTRUM REACTIVATORS OF OPNA-INHIBITION OF HUMAN CHOLINESTERASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017021319-A1 | BROAD SPECTRUM REACTIVATORS OF OPNA-INHIBITION OF HUMAN CHOLINESTERASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-02-09 | — | — | WO | disclosed |
| WO-2016023885-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023885-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | WO | disclosed |
| CN-101541751-A | Quinoline compounds | WYETH CORP (US) | 2009-09-23 | — | — | CN | disclosed |
| EP-2074098-A2 | QUINOLINE COMPOUNDS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503440-B2 | Nitroxoline derivative, preparation method therefor, and use thereof | NOS1, NQO1, NOS2 | HTR1A 3277/4885ADRA1D 1747/4885ADRA1A 1544/4885 |
| US-12291502-B2 | Topoisomerase II-alpha inhibitors and methods of treating cancer using the same | TOP2A, TOP1, TOP2B | HTR1A 4058/4885ADRA1D 4149/4885ADRA1A 3363/4885 |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | HTR1A 836/4885ADRA1D 481/4885ADRA1A 958/4885 |
| US-20170233345-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | NQO2, SIRT5, BRD4 | HTR1A 1386/4885ADRA1D 801/4885ADRA1A 739/4885 |
| US-12209090-B2 | 3,6-disubstituted-2-pyridinaldoxime scaffolds | XDH, TPX2, CYP4X1 | HTR1A 303/4885ADRA1D 129/4885ADRA1A 194/4885 |
| US-20250289826-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | ACE, PLP2, ACE2 | HTR1A 2785/4885ADRA1D 4840/4885ADRA1A 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.